
Telix Pharmaceuticals Appoints Dr Colin Hayward as Chief Medical Officer

Melbourne (Australia) – 2nd June 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') today announces that Dr Colin Hayward has joined Telix's executive leadership team in the role of Chief Medical Officer (CMO).

Dr Hayward joins Telix with over twenty years of global pharmaceutical, biotechnology and drug development experience and will lead the Company's medical affairs, regulatory, clinical operations and pharmacovigilance activities on a global basis. Dr Hayward holds a Bachelor of Medicine degree from the University of London and is a Fellow of the Faculty of Pharmaceutical Medicine (UK). Prior to joining Telix, Dr Hayward was the Chief Medical Officer of Premier Research (North Carolina, USA), a leading global Contract Research Organisation (CRO) specialising in the biopharmaceutical and specialty pharmaceutical areas of clinical research.

Dr Hayward has held a series of senior medical, executive and board level roles with F. Hoffmann-La Roche, Myriad Genetics, Prism Ideas Ltd and Symprove Ltd. Earlier in his career, Dr Hayward worked in the UK National Health Service with a clinical focus in intensive care and anaesthesia.

Telix CEO Dr Chris Behrenbruch stated, "Colin is a strong addition to the Telix executive leadership team. He brings significant international medical, commercial and leadership experience to Telix gained from pharmaceutical and specialty biotechnology companies. Colin has an extensive therapeutic background in oncology, including immuno-oncology, and a thorough understanding of the requisite steps involved in successfully taking late-stage cancer drugs to market. Colin's appointment substantially develops the international bench strength of the Company and provides a much-needed US-based clinical presence as we push our product pipeline toward commercialization."

With the appointment of Dr Hayward as Telix's full-time executive CMO, Telix co-founder Dr Andreas Kluge will transition from an Executive Director to a Non-Executive Director role.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.